Silver Book reference

Ranibizumab for Neovascular Age-Related Macular Degeneration

1 Matching Fact

Search matching Facts:
No results to display
    • Lucentis to treat wet age-related macular degeneration (AMD)
      An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25%…